Novartis AG (NVS) said Thursday that a phase 3 study of its drug Cosentyx combined with a 26-week steroid taper in adults with newly diagnosed or relapsing giant cell arteritis did not meet its primary endpoint of statistically significant improvement in sustained remission at 52 weeks compared with placebo plus a 52-week steroid taper.
While secondary outcomes also did not show statistical superiority, they showed "numerically better outcomes" compared to the placebo, the company said.
Novartis said it will complete a full evaluation of the study data and share the results later.
Giant cell arteritis is a common form of vasculitis that may cause vision loss and life-threatening aneurysms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.